GREG CUNY to Alzheimer Disease
This is a "connection" page, showing publications GREG CUNY has written about Alzheimer Disease.
Connection Strength
0.362
-
Inhibition of the GSK3?/Nav1.6 complex suppresses early-stage Alzheimer's hyperexcitability. Alzheimers Dement. 2025 Jul; 21(7):e70507.
Score: 0.138
-
Restored glial glutamate transporter EAAT2 function as a potential therapeutic approach for Alzheimer's disease. J Exp Med. 2015 Mar 09; 212(3):319-32.
Score: 0.067
-
Inhibitor of the tyrosine phosphatase STEP reverses cognitive deficits in a mouse model of Alzheimer's disease. PLoS Biol. 2014 Aug; 12(8):e1001923.
Score: 0.065
-
RNA therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine. Curr Alzheimer Res. 2006 Jul; 3(3):221-7.
Score: 0.037
-
FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein. J Mol Neurosci. 2004; 24(1):129-36.
Score: 0.031
-
Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models. J Biol Chem. 2013 Jul 26; 288(30):22042-56.
Score: 0.015
-
Defining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation. Chem Biol. 2005 Jul; 12(7):811-23.
Score: 0.009